Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal vs IM Glucagon for Hypoglycemia in T1DM
NCT03339453Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glucagon in hypoglycemia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at 30 months. Started Nov 2017; status: completed.
02
Drugs
glucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT03339453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339453.